Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart Disease
NCT03105219 · Nanjing First Hospital, Nanjing Medical University · PHASE3 · withdrawn · last registry update 2020-11-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Shortfall in funding” | – | Registry record, Nanjing First Hospital, Nanjing Medical University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HCN4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-06-29Results posted on the registry: University of California, San Diego, Ivabradine + Placebo (NCT03182725)
- 2020-11-06Results posted on the registry: Gilead Sciences, Ranolazine + Dronedarone (NCT01522651)
- 2020-08-17Also stopped (terminated): Bayside Health, Ivabradine + Metoprolol (NCT00825123)
- 2020-04-07Results posted on the registry: Amgen, Ivabradine (NCT03456856)
- 2020-03-13Also stopped (withdrawn): Policlinico Casilino ASL RMB, Ivabradine plus beta-blocker (bisoprolol) + betablocker titration (NCT01868880)
- 2020-03-13Phase 3 first posted: Chun-Yao Huang, Ivabradine 5 mg [Corlanor] + Digoxin 0.25 mg (NCT04308031)
- 2020-02-26Phase 3 first posted: Cairo University, Ivabradine + Conventional Treatment (NCT04285736)
- 2020-01-02Results posted on the registry: University of Leeds, Ivabradine + Placebo (NCT02247245)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision